Navigation Links
Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
Date:8/23/2007

ndpoint supporting its satraplatin New Drug Application ("NDA"); (4) that the FDA's evaluators would be unable to determine disease progression from the Company's NDA submission; and (5) that the interim data submitted with the NDA would not allow the FDA to conclude that satraplatin was more effective than placebo in terms of overall survival.

Throughout the Class Period, the Company reported positive results from its satraplatin Phase 3 trial, and indicated that data from the trial would form the Company's New Drug Application ("NDA") with the FDA. The Company reported a 40 percent reduction in risk of disease progression for study participants who received satraplatin, and reported that the study data showed that the results for PFS were highly statistically significant. The Company's investors were shocked on July 20, 2007, when the FDA released its "Briefing Document" in advance of the FDA's Oncology Drugs Advisory Committee's meeting to consider the satraplatin NDA. Therein, the FDA cited five "issues" that it had with the Company's satraplatin NDA. On this news, the Company's shares declined $7.80 per share, or over 24.5 percent, to close on July 20, 2007 at $24.00 per share, on unusually heavy trading volume. On the following trading day, the Company's shares declined an additional $3.05 per share, to close on July 23, 2007 at $20.95 per share.

Then on July 24, 2007, the FDA's advisory panel voted 12-0 to recommend delaying a decision on satraplatin until the Company gathered additional data to determine whether satraplatin actually helped men with prostate cancer live longer. In response, the Company disclosed that it did not expect to have the necessary survival analysis for another year. On this news, the Company's shares declined an additional $7.19 per share, or 35.36 percent, to close on July 25, 2007 at $13.16 per share, on unusually heavy trading volume.

Plaintiff seeks to recover damages on behalf of class members and is represente
'/>"/>

SOURCE Schiffrin Barroway Topaz & Kessler, LLP
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Doyle repeals shareholder liability
2. Why repealing the shareholder wage lien law makes sense
3. Merge president steps down in wake of shareholder suits
4. Pressure mounts for Doyle to repeal shareholder liability law
5. Merges merger is the crux of shareholder lawsuits
6. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
7. Screening and classifying hazardous waste samples
8. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
9. Early Stage, Step 8: Misclassifying workers brings risk
10. Healthcare software addresses "90 million" misclassified Americans
11. Classroom projects translate into immediate workplace gains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... “Our nation's healthcare system is broken, ... Furthermore, every governmental and professional entity that has ... of unorganized dysfunction shares in that enormous blame. ... as a device to use in an effort ... have accumulated through the years leading to the ...
(Date:8/21/2014)... for Molecular Medicine Finland (FIMM), University of Helsinki, ... "man and machine" decision support system for diagnosing ... in PLOS One scientific journal today, ... vision algorithms similar to those used in facial ... diagnostically most relevant areas. Tablet computers can be ...
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... August 21, 2014 The College of ... private college in the Mid-Hudson Region to be designated ... begin accepting applications from qualified “high-technology” businesses that align ... very pleased to have been selected for the START-UP ... transformative initiative to stimulate economic development in New York ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3
... ... ... 2009 -- As part of ongoing efforts to expand deployment of 21st century environmental ... soil , sediment and groundwater remediation industry, is pleased to announce formal ...
... SEATTLE, Dec. 8 Dendreon Corporation (Nasdaq: DNDN ) ... subject to market and other conditions, of 15,000,000 shares of ... Dendreon intends to grant to the underwriters a ... of common stock to cover over-allotments, if any. J. ...
... OMAHA, Neb., Dec. 8 Transgenomic, Inc. (OTC Bulletin Board: ... kit, the first in a family of mutation detection kits ... and WAVE ® HS DHPLC platform. SURVEYOR Scan ... a PCR amplification reaction and hybridization to form heteroduplex DNA ...
Cached Biology Technology:Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4Dendreon Announces Proposed Public Offering of Common Stock 2Dendreon Announces Proposed Public Offering of Common Stock 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4
(Date:8/21/2014)... A team of researchers at Louisiana ... for using affordable, consumer-grade 3D printers and ... can contain antibacterial and chemotherapeutic compounds for ... of doctoral students and research faculty from ... programs collaborated to create filament extruders that ...
(Date:8/20/2014)... 158 pregnant teenagers in Rochester, NY, nearly half engaged ... ice, cornstarch, vacuum dust, baby powder and soap, and ... Moreover, such teens had significantly lower iron levels as ... , Pregnant teens, regardless of pica, are at higher ... deficiency and anemia. Low iron in pregnant teens raises ...
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Pica in pregnant teens linked to low iron 2
... Changes to proteins in a cell underlay many cancers. ... in Portugal, in collaboration with researchers in Ghent (Belgium) ... understand exactly how changes to proteins, identified in the ... living organism. This study, funded by the Association for ...
... In prehistoric times farmers across the world domesticated ... result the ancestral plants have been lost, causing problems ... but that might change. A team led by Fabiola ... has managed to trace a domesticated cactus, the Gray ...
... (August 23, 2010) A clue to the causes ... the tiny intercellular junction that rapidly transfers information from ... Tufts University School of Medicine, with students from the ... protein called APC (adenomatous polyposis coli) plays a key ...
Cached Biology News:Understanding cancer using the fruit fly 2Cactus genes connect modern Mexico to its prehistoric past 2Researchers connect APC protein to autism and mental retardation 2
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... is a competitive enzymeimmunoassay (EIA) for the ... rat serum or plasma. Corticosterone is the ... and mice, and in most non-mammalian vertebrates ... mammals produce both corticosterone and cortisol, in ...
Biology Products: